Up­dat­ed: GSK taps Chi­nese part­ner to ramp up Shin­grix sales in $3.05B deal, with op­tion to ex­pand to RSV

GSK is tap­ping a heavy­weight part­ner to co-pro­mote its block­buster shin­gles vac­cine Shin­grix in Chi­na — and lock­ing in £2.5 bil­lion ($3.05 bil­lion) over the next …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.